Sector News

Astellas names James Robinson President, Americas Operations

February 8, 2016
Life sciences

/PRNewswire/ – Astellas Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka today announced the promotion of James Robinson as president, Americas Operations, for Astellas US LLC, with responsibility for the company’s operations in North and South America, effective April 1, 2016. Robinson previously served as president, Astellas Pharma US, representing the commercial organization in the United States — a role he assumed in 2013.

Robinson will succeed Masao Yoshida, who is retiring in June 2016.

“As a 10-year veteran of Astellas with more than 20 years of healthcare industry experience, Jim’s commitment to operational and commercial excellence has helped Astellas grow dramatically in the Americas,” said Hatanaka. “His deep experience, skills and strong commitment to operating and leading with the highest sense of ethics and compliance will help Astellas stay focused on our global vision to be on the forefront of healthcare change to turn innovative science into value for patients.”

“Astellas is respected for its unwavering focus on supporting patients. This foundational idea is our compass for continued growth in the Americas,” said Robinson. “We will remain committed to serving patients, pursuing operational excellence within the organization and building Astellas’ presence throughout the Americas.”

Robinson joined Astellas in 2005 as the vice president of health systems, responsible for managed markets, reimbursement strategy, state government affairs and government accounts, and has since held positions of increasing responsibility. In 2011, Robinson was named senior vice president, sales and marketing, leading the US organization responsible for sales, marketing, new product planning, market access and commercial operations.

Robinson began his career at Schering-Plough in 1992 as a sales representative, and held positions of increasing responsibility until he was promoted to vice president of hepatitis sales and managed care in 2003. In this position, he led the largest specialty pharmaceutical sales division within Schering-Plough until he joined Astellas.

He serves as chairman of the Pharmaceutical Research and Manufacturers of America State Committee, is a member of the BioScience council for ChicagoNEXT and serves on the board of directors of MATTER. He is member of The Commercial Club of Chicago and is a graduate of DePaul University.

Source: Astellas

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach